Premium
Drugs against leishmaniasis: Overview of market needs and pipeline
Author(s) -
Golgher Denise,
Vianna Cláudia Hamacek,
Moura Adriana Cláudia
Publication year - 2011
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20453
Subject(s) - pipeline (software) , drug development , leishmaniasis , business , drug discovery , drug , risk analysis (engineering) , medicine , computer science , pharmacology , immunology , biology , bioinformatics , programming language
The goal of this article is to provide an overview of market needs and opportunities regarding the development of new drugs against leishmaniasis, an emergent infection that is spreading throughout the world. We provide an analysis of the current pipeline and discuss how the new scenario in drug discovery and development for neglected diseases may favor the entry of smaller players in the market of new therapeutics. Drug Dev Res 72:463–470, 2011. © 2011 Wiley‐Liss, Inc.